AVIR

Over the past six months, Atea Pharmaceuticals' stock price increased by 76.90% from October 3, 2025, to October 2, 2026, and gained 77.4% over the last year, though it saw a -12.12% change in the past six months. Key events impacting the stock include positive topline results from its Phase 3 C-BEYOND trial for the bemnifosbuvir/ruzasvir regimen for HCV in July 2026, which met primary and secondary endpoints with a 93.9% sustained virologic response rate. In August 2026, Atea reported its Second Quarter 2026 Financial Results and provided a business update. The stock experienced its largest daily move, a decrease of -16.91%, on May 13, 2026. In June 2026, the stock was upgraded to a Zacks Rank #2 (Buy), and in May 2026, it became technically oversold. Atea's Q1 earnings call in May 2026 highlighted being on track for two key Phase 3 hepatitis C readouts and advancing a hepatitis E program, with the average one-year price target increased by 25.00% to $10.20/share. In September 2026, Atea Pharmaceuticals announced it would present at the Morgan Stanley 24th Annual Global Healthcare Conference.